Newsletter

326030 - SK biopharmaceuticals Co., Ltd.

326030 Summary
Biopharma
Stock Price & Overview
₩86,600 +200 (+0.23%) Close · Sep 4, 2026 KST
KOSPI | ₩KRW | Close: ₩86,600  ≈ US$62  ·  Market cap ₩6.8tn (≈ $4.8bn)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

326030 DART Filings

DART

Large business group status disclosure — quarterly, individual company

Filing08/27/26title translated
DART

Material event report (significant asset transfer, other)

Filing08/26/26title translated
DART

Material matter: in-licensing deal for Opakalim and other epilepsy drug candidates

Filing08/26/26title translated
DART

Single Supply Contract Signed

Contract08/18/26title translated
DART

Half-Year Report

Periodic08/14/26title translated
DART

Supplier Payment Terms and Dispute-Resolution Disclosure

Governance08/14/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings08/05/26title translated
DART

Single Supply Contract Signed

Contract07/28/26title translated
DART

Increase in short-term borrowings

Filing06/29/26title translated
DART

Material matter: joint research and development partnership signed with Insilico Medicine

Filing06/22/26title translated
DART

Sustainability report (voluntary)

Filing06/19/26title translated
DART

Corporate governance report

Filing06/01/26title translated
DART

Large business group status disclosure — annual and Q1, individual company

Filing05/29/26title translated
DART

Single Supply Contract Signed

Contract05/27/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings05/07/26title translated
7 routine filings (insider holdings reports, IR schedules)DART

Change in the Largest Shareholder's Holdings

Ownership08/31/26title translated
DART

Insider / Major Shareholder Holdings Report ×2

Ownership08/31/26title translated
DART

Investor Relations Event

IR08/26/26title translated
DART

Investor Relations Event

IR08/03/26title translated
DART

Investor Relations Event

IR05/26/26title translated
DART

Investor Relations Event

IR05/19/26title translated
DART

Investor Relations Event

IR05/04/26title translated
23 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 326030

SymbolLast Price
128940Hanmi Pharm. Co., Ltd.₩473,500
+2.8%
000100Yuhan Corporation₩81,400
+0.0%
028300HLB Co., Ltd.₩33,750
+2.9%
298380ABL Bio Inc.₩71,400
+5.6%
000250Samchundang Pharm₩157,000
+1.0%
087010Peptron, Inc.₩157,300
+7.3%
141080LigaChem Biosciences Inc.₩92,000
+4.2%
145020Hugel, Inc.₩244,000
+1.5%
302440SK Bioscience Co., Ltd.₩37,900
+0.4%
009420Hanall Biopharma Co., Ltd.₩54,700
+1.5%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.